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Abstract
There  is  evidence  that  insertion  of  viral  DNA into  a  mammalian  genome  can  lead  to 
alterations of methylation patterns. The aim of the present study was to examine the presence 
of DNA sequences of  five human DNA viruses (assessed by PCR): JC polyoma virus (JCV), 
human adenovirus (AdV), Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus 
(KSHV/HHV8)  and  human papillomavirus  (HPV) in  a  cohort  of  186 sporadic  colorectal 
cancers (CRCs) and related these data with the methylation status of six CIMP-specific genes 
(MLH1,  CACNA1G,  NEUROG1,  IGF2,  SOCS1,  RUNX3) and  seven  cancer-related  genes 
markers (p16, MINT1, MINT2, MINT31, EN1, SCTR and INHBB) assessed by methylation-
specific  PCR in  186 and 134 CRC cases,  respectively.  The  AdV,  KSHV and HPV were 
detected  in  4 (2%),  2 (1%) and 0 CRC cases,  respectively and thus  were excluded from 
further  analyses.  Althought,  19% and  9% of  the  CRCs  were  positive  for  EBV and  JCV 
respectively, no associations between virus presence and CpG island methylation were found 
after  correction  for  multiple  testing. Our  results demonstrate  that  the  presence  of  DNA 
sequences of  JCV and EBV in CRC is unrelated to the methylation of the 13 cancer-related 
CpG islands and CIMP. 
Background
The  process  of  DNA  methylation  in  human  cells  are  controlled  by  DNA 
methyltransferases  (DNMTs).  DNMTs  catalyze  the  transfer  of  a  methyl  group  from  the 
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methyl donor to the 5′ position on the cytosine ring [1]. CpG island methylation is prevalent in 
human sporadic cancers resulting in the transcriptional silencing of many important genes [2]. 
Abberant CpG island methylation is one of the hallmarks of sporadic CRC and in this context 
it  has  been  observed  that  a  subset  of  CRCs  exhibit  an  exceptionally  high  frequency  of 
methylation  of  discrete  CpG islands  referred  to  as  the  CpG island methylator  phenotype 
(CIMP) [3]. Although the mechanism responsible for abberant CpG island methylation and/or 
CIMP has not yet been elucidated, there is mounting evidence that infectious agents, such as 
DNA viruses, may cause aberrant methylation in CRCs [4]. 
Evidence that DNA viruses influence aberrant methylation comes from the observation 
that insertion of adenovirus (AdV)  DNA into a mammalian genome can lead to alterations of 
methylation patterns in cellular DNA [5]. Moreover, a two recent studies have reported that 
Epstein-Barr virus (EBV) transformed lymphoblastoid cell  lines demonstrate  alterations of 
methylation patterns when compared to  peripheral blood leukocytes [6,7]. Finally, abberant 
methylation of p16 tumor suppresor gene has been reported in  Kaposi sarcoma-associated 
herpesvirus (KSHV/HHV8) associated primary efusion lymphoma.  It was also demonstrated 
repeatedly that  various viral  proteins interact  with a number of  host epigenetic  regulators 
which may contribute to alternations in DNA methylation and histone modifications  [8]. The 
AdV small E1A protein binds to  DNA methyltransferase 1 (DNMT1), increases its activity 
and alters  global  patterns  of  histone  modification  [9]. The human papillomavirus  type  16 
(HPV16)  E6  oncoprotein  interacts  with  and  thus  inhibits  the  histone  acetyltransferase 
CBP/p300 complex, whereas the E7 oncoprotein binds to the  histone deacetylase complex 
Mi2β [10]. The  KSHV  (HHV8)  LANA protein  activates  DNMT3a  facilitating  de  novo 
promoter methylation [11]. The  EBV latent membrane protein 1 (LMP1) activates all three 
human DNMTs, which increases de novo promoter methylation [12]. Although none of the JC 
virus  (JCV)  proteins  have  been  reported  to  interact  with  any  epigenetic  regulator,  some 
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previous  reports  have  suggested  a  link  between  expression  of  the  JCV  T-antigene  and 
extensive promoter methylation leading to methylator phenotype (CIMP) in colorectal cancer 
(CRC) [13]. 
In this study we assess the presence of DNA sequences from five viruses (JCV, EBV, 
AdV, KSHV (HHV8) and HPV) in CRCs in relation to methylation of a number of cancer-
related genes as well as to CIMP.
Methods
Patients. The  study was  performed on 186 surgically  resected  frozen tissues  of  sporadic 
CRCs that were obtained between 2001 and 2008 from the 2nd Department of General and 
Oncological Surgery, Wroclaw Medical University and the Department of General Surgery, 
Regional Specialized Hospital, Wroclaw. 
The  CRC patient’s  group  consisted  entirely  of  Polish  individuals  (all  Caucasians).  Only 
patients with primary, sporadic colorectal cancer who had not received preoperative therapy 
were included into the studies. Informed consent was obtained from all patients. The study 
was accepted by the Wroclaw Medical University Ethics Committee.
BRAF V600E mutation. Detection of BRAF V600E in tumor tissues was carried out using a 
procedure orginally described by Sapio et al. [14]. Briefly, mutant allele-specific PCR was 
used to amplify the exon 15 region of the BRAF gene. PCR products with an expected size of 
125 bp were resolved on a 2.5% agarose-ethidium bromide gel. 
Bisulfite Treatment of DNA, Methylation-Specific PCR and CIMP. Bisulfite treatment of 
genomic DNA obtained from resected frozen tumor tissues was carried out using a procedure 
described by Chan et al. [15]. Approximately 50 ng of the modified DNA was amplified in a 
PTC 200  DNA Engine  Thermal  cycler  (MJ  Research,  Inc.  Waltham,  MA)  with  primers 
specific  to  either  the  methylated  or  unmethylated  promoter  sequences  of  the  CACNA1G, 
IGF2, NEUROG1, RUNX3, SOCS1, hMLH1, p16, MINT1, MINT2, MINT31, EN1, SCTR and 
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INHBB genes.  The primer sequences  and amplification conditions  of  methylation-specific 
PCR utilized in this study are described elsewhere [3,15,16]. CIMP was defined by the use of 
a specific panel of markers and citeria described by Weiseberger et al.  [3]. Briefly, after the 
analysis of the methylation of a panel of 5 markers (CACNA1G, IGF2, NEUROG1, RUNX3 
and SOCS1), CIMP+ tumors were defined as those with at least 3 methylated CIMP markers. 
CIMP- tumors were defined as those with at most 2 methylated CpG islands.
Viral  DNA amplification. Firstly,  all  samples  were  examined  for  DNA integrity  using 
amplification of the β-globin gene. Great care was taken to avoid specimen contamination 
during the course of this investigation. Sample preparation, electrophoresis and PCR solution 
preparation  were  conducted  in  physically  separated  laboratory  areas.  The  viral  sequences 
were amplified using a single PCR approach to avoid false-positives and ensure reliable PCR 
detection. For JCV, KSHV (HHV8) and EBV we used species-specific PCR primers [13,17]. 
As the HPV and AdV are species with a high degree of genetic heterogeneity, we used broad-
spectrum PCR primers that permit the simultaneous amplification of a range of HPV or AdV 
types in a single PCR test [18,19]. A negative control was included in each PCR assay. All 
samples were reexamined for the presence of viral DNA. All positive samples for EBV and 
JCV were confirmed using restriction enzyme digestion. 
All PCR reactions were carried out separately in a 25µl reaction volume containing 1x PCR 
buffer (Qiagen),  1.5 mmol/L MgCl2, 200 µmol/L deoxynucleoside triphosphate,  50 ng of 
genomic DNA, 0.2 µmol/L of each primer,  and 0.75 units  of  Hot-Start  DNA polymerase 
(Qiagen). All PCR reactions were run under the conditions described in the references, except 
for an initial denaturation period of 15 min at 95°C, which we applied in all tests.  Primer 
sequences and related references are shown in Table 1. All positive controls were purchased 
from  Advanced  Biotechnologies  Inc  (Columbia,  Maryland)  except  of  HPV,  where  DNA 
obtained from larynx  tumor positive for HPV 16 was applied (see Table 1).
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Statistical analysis. The Pearson chi-squared test (if all expected cell frequencies were ≥ 5) or 
Fisher’s exact test  was used to test whether the presence of a virus is associated with the 
methylation of a CpG island or CIMP status. All  p-values were two-sided and  Bonferroni 
correction was taken into consideration because of the multiple comparisons carried out in this 
study.  The R statistical  package  was used  to  carry  out  the  necessary statistical  tests  and 
calculate the confidence intervals for the odds ratio.
Results
Study group and CIMP classification. We examined the CIMP status of 186 sporadic CRCs 
by  methylation-specific  PCR  using  a  CIMP  specific  marker  panel  (CACNA1G,  IGF2,  
NEUROG1, RUNX3 and SOCS1) [3]. The characteristics of study group, both overall and with 
respect to CIMP status, are shown in Table 2. On the average, the CIMP+ cases tended to be 
older than CIMP- cases, however, this differences did not attain statistical significance. There 
were no significant differences between CIMP- and CIMP+ cases in sex distribution. Since 
CIMP was defined as the presence of at least 3 methylated sites out of the 5 studied loci, 25% 
(46/186) of the tumors were classified as CIMP+. A strongly bimodal distribution of tumors 
according to the number of methylated loci was observed (Figure 1). To examine whether our 
CIMP classification was adequate, we determined the presence of the BRAF V600E mutation 
and  MLH1 methylation.  We observed  a  significant  association  of  both  the  BRAF V600E 
mutation and MLH1 methylation with CIMP+ tumors (OR = 12.33, 95% CI = 4.21-41.54; P = 
1.8 × 10-7 and OR = 15.5, 95% CI = 4.54-68.65; P = 2.8 × 10-7, respectively). These results, 
together with the strongly bimodal distribution of the number of methylated tumors in our 
cohort proved that our CIMP classification was appropriate.
Detection of viral DNA sequences in colorectal cancers. In the current study, we analyzed 
186 cases of sporadic colorectal tumors (all amplifiable with a β-globin primer set) for the 
presence  of five viruses (JCV, AdV, EBV, KSHV (HHV8) and HPV) using PCR. The AdV, 
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KSHV and HPV were detected in 4 (2%), 2 (1%) and 0 CRC cases, respectively and thus 
these species were excluded from the statistical analyses. 19% (36/186)  cases were positive 
for EBV and 9% (17/186) of the cases were positive for JCV. There was no relationship 
between the presence of EBV and JCV and sex (see Table 3). 
Relationship of JCV and EBV with CIMP and methylation in CIMP markers. The overall 
results  on the  presence  of  EBV and JCV according to  CIMP and methylation  of  CIMP-
specific markers are presented in Table 3 and Figure 1. The presence of JCV was significantly 
less common in tumors with at least one methylated CIMP specific marker (5.6% (7/124); P = 
0.03) than in the group without methylated CIMP specific markers (16% (10/62)), Figure 1. 
We also examined the relationship of EBV and JCV with methylation for each CIMP specific 
marker individually (Table 3). In this analysis EBV was inversely associated with methylation 
of RUNX3 (P = 0.048) and JCV was inversely associated with methylation of CACNA1G (P = 
0.03). However, these associations became nonsignificant after correction for multiple testing.
Relationship of JCV and EBV with methylation in individual CpG islands. Because JCV 
and EBV have been implicated in CpG island methylation,  we examined the relationship 
between the presence of these two species and methylation in 7 individual CpG islands (Table 
4). For this analysis we were able to use 134 of the 186 CRCs due to the limited availability 
of DNA from the tumors. In this analysis JCV showed an inverse association with methylation 
of  MINT1  (P = 0.04). However, this association became nonsignificant after correction for 
multiple testing
Conclusions
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Epigenetic alternations play a key role in the process of colorectal carcinogenesis [20]. 
The  recently  described CpG island methylator  phenotype  (CIMP) in  sporadic  CRC is  an 
alternative  tumorigenesis  pathway  characterized  by  the  methylation  of  multiple  promoter 
regions of tumor suppressor genes harboring CpG islands [3]. Paradoxically, despite dozens 
of studies, the defects in the methylation machinery leading to CIMP in CRC remain still  
unidentified [4].
Several  lines of evidence suggest  that a number of viral  proteins interact  with the 
host’s epigenetic machinery, most likely to evade detection by the host’s immune system  [8]. 
Moreover,  experimental  approaches,  such  as  transfection  of  mammalian  cells  with  an 
adenovirus, demonstrate that insertion of viral DNA can alter the host’s DNA methylation 
patterns regardless of the transcription state of the viral genome  [5,21]. Further evidence of 
virus-induced  alternations  in  host’s  DNA  methylation  patterns  was  observed  in  EBV 
transformed lymphoblastoid cells [6,7]. Therefore, the DNA viruses such as JCV, AdV, EBV, 
KSHV (HHV8) and HPV seemed to be reasonable candidates for being a causative agents of 
alterations in DNA methylation resulting in CIMP in sporadic CRC.
In the present study  AdV and KSHV (HHV8) were detected in 4 and 2 CRC cases, 
respectively. Hence, these species were excluded from further analyses. Of note, the very low 
frequency  of  infections  in  our  CRC group by these  species  are  in  agreement  with  those 
reported by Knösel et al. [22], who studied various infectious pathogens in Crohn’s disease.
In our CRC group no positive signals (0/186) were obtained for HPV. HPV DNA has 
been  detected  in  CRCs  by  others  with  a  frequency  ranging  from  50% to  80% [23-25].  
Interesingly, in the all of above-mentioned reports a nested PCR was employed to detect HPV. 
In our opinion, this detection technique is likely to introduce a high rate of false positives or 
the detection of insignificant virus load in the sample, which leads to overestimation of virus 
presence in the sample, therefore, we decided to stay in line with a single PCR approach for 
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all virus species investigated in this study. In agreement with our strategy, the results of Atula 
et al. [26] suggest that HPV DNA detected by nested PCR in laryngeal carcinoma cell lines is 
likely to relate to the presence of minimal amounts of HPV (20 HPV-positive cells among 106 
tumor  cells)  suggesting  non-clonal  persistence  of  HPV  in  laryngeal  carcinomas.  Most 
importantly, we were able to amplify HPV DNA from larynx cancer samples by our PCR 
approach (data not shown)  which further suggests lack or minimal amounts of HPV copies in 
our CRC cohort.
Of the other viruses examined,  EBV was the most  frequent pathogen (19% of the 
cases). Few papers have been also published on the presence of EBV in CRCs, moreover with 
contradicting results. EBV DNA has been detected in CRCs with a frequency ranging from 
0% to 19% [27-29]. In great majority of above-mentioned studies EBV has been detected by 
using in situ hybridisation of the small EBV-encoded RNA1 (EBER1) which is believed to be 
consistently expressed in EBV infection. However, an EBER-negative form of EBV infection 
has been observed in breast  cancers and hepatocellular carcinoma and therefore a lack of 
detectable EBNA1 expression cannot be taken as proof of absence of the virus [30,31].   Since 
in the present study we used DNA obtained from resected tumors, it is possible that some of 
the EBV positive signals reflect the presence of tumor-infiltrating lymphoctes (TILs) in the 
tumour stroma that carry EBV rather than the presence of EBV-positive tumor cells.  However, 
Yoshiyama et al. [32] and others reported that EBV is able to infect epithelial cell lines  in  
vitro only by co-culture with EBV-infected B cells, therefore the contribution of EBV-positive 
TILs (as possible EBV transmitters) in pathogenesis of colon cancer can not be completely 
excluded [33]. 
In general, EBV was not associated either with the CIMP phenotype or methylation of 
any of the individual CpG islands studied, except for an inverse association with methylation 
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in one of the CIMP specific markers (RUNX3)  (nonsignificant after correction for multiple 
testing). 
The second most frequent virus in our CRC group was JCV (9% of the cases). As in 
the case of  prevalence of HPV in CRCs, the papers  published on the presence of  JCV T-
antigen sequence in CRCs display contradictory results with frequencies ranging from 0% in 
Italian  and  Spanish  study, through  26% in  Japanese  cases to  77% in  American  patients 
[13,34,35,36].  Given the all above-cited studies based on relatively similar PCR approaches 
the discrepancies of JCV frequencies in CRC may reflect ethnic-dependent epidemiology of 
JCV or lack of reliable and reproducible test for the detection of JCV DNA [37]. A previous 
study by Goel  et  al.  [13]  reported  an association  between JCV T-antigen expression and 
methylation of the promoter region of various cancer-related genes in colorectal cancer. Goel 
et al. [13] also hypothesized that the JCV T-antigen may be responsible for induction of the 
methylator phenotype in CRC. Contrary to these results, we found that the presence of JCV T-
antigen sequence was less common in tumors with at least one methylated CIMP specific 
marker.  Moreover,  we showed that  among the CRC cases  the presence  of JCV T-antigen 
sequence was inversely associated with methylation in two CIMP-related genes (CACNA1G 
and MINT1). Although these associations became nonsignificant after correction for multiple 
testing it did not escape our attention that the presence of JCV T-antigen sequence show some 
tendency towards unmethylated CpG islands. Similar results were presented in a very recent 
paper by Nosho et al. [38], who observed an inverse association of JCV T-antigen expression 
with CIMP and a lack of association with methylation in 16 genes in a large sample of CRCs.  
Interesingly, some recent reports show very strong evidence that JCV T-antigen interacts with 
p53 and Rb family proteins and therefore may induce chromosomal instability (CIN), which 
is a largely independent from the CIMP pathway in colorectal carcinogenesis [39,40].  The 
independence of the CIN and CIMP pathways in sporadic CRC manifests itself via the high 
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level of chromosomal aberrations in tumors with none of the CIMP markers methylated   [41]. 
The  more  common  presence  of  JCV  in  a  group  of  CRCs  without  any  CIMP  marker 
methylated  revealed  by  our  study  provides  some  support  to  the  notion  that  JCV  may 
contribute to CIN in a fraction of CRC cases [38].
A potential limitation of this study is that DNA methylation investigation was limited 
to  several  CpG islands,  therefore  the  influence  of   presence  of  JCV and  EBV on DNA 
methylation in CRC needs to be further elucidated on the genome-wide scale. Finally, further 
research is  needed to assess the relationship between virus load and DNA methylation in 
CRC.
In summary, our study provides no evidence of involvement of  AdV, KSHV (HHV8) 
and HPV in  pathogenesis  of CRC in Polish population.  The presence of  JCV and EBV 
sequences in CRCs was not related to methylation of the 13 cancer-related CpG islands and 
CIMP. 
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Figure 1. Bimodal distribution of the number of methylated CIMP-specific markers in 186 
colorectal tumor specimens with relation to EBV and JCV presence
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Table 1. Primer sequences used in this study
Primer sequences (5’→3’) Target 
sequence
Product size Positive control Reference
β-globin
GlobinF   ACACAACTGTGTTCACTAGC
GlobinR   GGAAAATAGACCAATAGGCTG β-globin 225bp (17)
EBV
EBVF   GATTTGGACCCGAAATCTGAT
EBVF   TCTGGGGGCTTATTCCTCTT
EBV BamHI W 
repeat 201bp EBV B95-8 Strain (17)
KSHV 
(HHV8)
ORFK9F   GTCTCTGCGCCATTCAAAAC
ORFK9R   CCGGACACGACAACTAAGAA vIRF-1 184bp
KSHV/HHV-8 KS-
1 Strain (17)
AdV
Hex3   GACATGACTTTCGAGGTCGATCCCATGGA
Hex4   CCGGCTGAGAAGGGTGTGCGCAGGTA hexon gene 139bp Adenovirus-2 
Infected Cell DNA
(19)
HPV
HPVpU- M  TGTCAAAAACCGTTGTGTCC
HPVpU-31B TGCTAATTCGGTGCTACCTG
HPVpU-2R GAGCTGTCGCTTAATTGCTC
E6 and E7 
regions
228~268 bp HPV-16 positive 
larynx tumor DNA
(18)
JCV
JCVF   ATGTATTCCACCAGGATTCCCATTCATC
JCVR   AGTTCTTGGAGACACCCCCTACAG large T antigen 154bp JCV MAD1 Strain (13)
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Table 2. Characteristics of CRC patients and control subjects
Variable All CRCs 
(n=186)
CIMP+ CRCs
(n=46)
CIMP - CRCs
(n=140)
p-value
Age  (SDa) 65 (±10) 68 (±11) 64 (±10)
b2.8×10-7
b1.8×10-7
Male (%) 105 (56) 28 (61) 77 (56)
Female (%) 81 (44) 18 (39) 63 (44)
hMLH1 (%)
Positive
Negative
19   (10)
167 (90)
15 (33)
31 (67)
4    (3)
136 (97)
BRAF V600E 
(%)
Positive
Negative
23   (12)
163 (88)
17 (37)
29 (63)
6    (4)
134 (96)
Right-sided
Left-sided 
No info
24 (21)
85 (79)
       77
10 (37)
17 (63)
14 (18)
68 (82)
     c0.02
a SD - standard deviation
bp-value refers to Fisher’s exact test 
cp-value refers to Pearson’s chi-squared test
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Table 3. Frequency of JCV and EBV in 186 colorectal cancers in relation to CIMP and methylation of CIMP markers
    a  p-value refers to Fisher’s exact test
Marker Total EBV+ 
(%)
EBV- 
(%)
p-value JCV+ 
(%)
JCV- (%) p-value
186 36 (19) 150 (81) 17 (9) 169 (91)
male
female
105
81
18 (17)
18 (22)
87 (83)
63 (78)
0.46 10 (10)
7 (9)
95 (90)
74 (91)
1.00
CIMP + 
CIMP - 
46
140
6 (13)
30 (21)
40 (87)
110 (79)
0.21 3 (7)
14 (10)
43 (93)
126 (90)
0.57
n CpG ≥ 1
n CpG = 0
124
62
24 (19)
12 (19)
100 (81)
50 (81)
1.00 7 (6)
10 (16)
117 (94)
52 (84)
0.03
BRAF (+)
BRAF (-)
23
163
1 (4)
35 (21)
22 (96)
128 (79)
0.08a 0 (0)
17 (10)
23 (100)
146 (90)
0.13a
MLH (+)
MLH (-)
19
167
2 (11)
34 (20)
17 (89)
133 (80)
0.54a 1 (5)
16 (10)
18 (95)
151 (90)
0.70a
CACNA1G (+)
CACNA1G (-)
69
117
9 (13)
27 (23)
60 (87)
90 (77)
0.12 2 (3)
15 (13)
67 (97)
102 (87)
0.03
IGF2 (+)
IGF2 (-)
44
142
5 (11)
31 (12)
39 (89)
111 (88)
0.19 4 (9)
13 (9)
40 (91)
129 (91)
1.00
NEUROG1 (+)
NEUROG1 (-)
72
114
16 (22)
20 (18)
56 (78)
94 (72)
0.45 3 (4)
14 (12)
69 (96)
100 (88)
0.07
RUNX3 (+)
RUNX3(-)
62
124
7 (11)
29 (23)
55 (89)
95 (77)
0.048 3 (5)
14 (11)
59 (95)
110 (89)
0.18
SOCS1 (+)
SOCS1 (-)
51
135
10 (20)
26 (19)
41 (80)
109 (81)
1.00 4 (8)
13 (10)
47 (92)
122 (90)
1.00
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Table 4. Frequency of JCV and EBV in 134 colorectal cancers in relation to methylation of individual cancer-related CpG islands
Marker Total EBV+ 
(%)
EBV- 
(%)
p-value JCV+ 
(%)
JCV- (%) p-value
134 22 (16) 112 (84) 13 (10) 121 (90)
p16 (+)
p16 (-)
44
90
  8 (18)
14 (16)
36 (82)
76 (84)
0.80   2 (5)
11 (12)
42 (95)
79 (88)
0.22
MINT1 (+)
MINT1 (-)
34
100
  4 (12)
18 (18)
30 (88)
82 (82)
0.59   0 (0)
13 (13)
34 (100)
87 (87)
0.04
MINT2 (+)
MINT2 (-)
53
81
  6 (11)
16 (20)
47 (89)
65 (80)
0.23 5 (9)
8 (10)
48 (91)
73 (90)
1.00
MINT31 (+)
MINT31 (-)
49
85
  6 (12)
16 (19)
43 (88)
69 (81)
0.46 6 (12)
7 (8)
43 (88)
78 (92)
0.55
EN1 (+)
EN1 (-)
45
89
  8 (18)
14 (16)
37 (82)
75 (84)
0.80 5 (11)
8 (9)
40 (89)
81 (91)
0.76
SCTR (+)
SCTR (-)
113
21
19 (17)
  3 (14)
94 (83)
18 (86)
1.00 12 (11)
  1 (5)
101 (89)
  20 (95)
0.69
INHBB (+)
INHBB (-)
38
96
  5 (13)
17 (18)
33 (87)
79 (82)
0.61 4 (11)
9 (9)
34 (89)
87 (91)
1.00
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